BRCTFOTCHealthcare · Biotechnology

BioArctic AB (publ)

$33.02+0.00%(+$0.00)

TickerSpark Score

76/100

Solid

Valuation

Profitability

100

Growth

100

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRCTF research report →

52-Week Range74% of range

Low $18.52

Current $33.02

High $38.06

Companywww.bioarctic.se

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries.

CEO: Gunilla Osswald
IPO: 2022
Employees: 107
HQ: Stockholm, SE

Price Chart

+73.88% · this period

Valuation

Market Cap: $2.93B
P/E: 128.78
P/S: 23.91
P/B: 12.49
EV/EBITDA: 60.84
Div Yield: 0.00%

Profitability

Gross Margin: 94.13%
Op Margin: 34.50%
Net Margin: 18.59%
ROE: 10.44%
ROIC: 8.88%

Growth & Income

Revenue: $1.99B · 674.85%
Net Income: $1.02B · 675.88%
EPS: $11.52 · 676.00%
Op Income: $1.36B
FCF YoY: 100.00%

Performance & Tape

52W High: $38.06
52W Low: $18.52
50D MA: $33.02
200D MA: $32.69
Beta: -0.78
Avg Volume: 5

Get TickerSpark's AI analysis on BRCTF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime